Synexa Life Sciences B.V.. (10/7/24). "Press Release: Synexa Life Sciences Expands Bioanalysis Capabilities with the Acquisition of CRO Alderley Analytical". Leiden.

	Region	Macclesfield, Cheshire
	Country	United Kingdom (GB)
	Organisation	Synexa Life Sciences B.V.
	Group	Synexa Life Sciences (Group)
	Organisation 2	Alderley Analytical Ltd.
	Group	Synexa Life Sciences (Group)
	Product	analytical services
	Product 2	mass spectrometry services (MS services)
	Index term	Alderley Analytical–Synexa Life Sciences: investment, 202410 acquisition of Alderley Analytical Ltd by Synexa
	Person	Lens, Emile (Synexa Life Sciences 202205 CEO before Avania + Maxeda DIY + ABN AMRO)
	Person 2	Holme, Paul (Alderley Analytical 202410 CEO + Co-Founder)

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based near Manchester, UK.

This transaction reflects an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning the company’s vision to become ‘the scientific partner of choice for biomarker and bioanalytical solutions’.

Alderley Analytical’s services complement Synexa Life Sciences’ established capabilities in biomarker and bioanalytical assays—covering DNA, RNA, protein, cell, and tissue analysis.

Specialising in mass spectrometry and ligand binding assays, Alderley Analytical offers a full range of bioanalytical services to support discovery, preclinical, and clinical drug development projects in small molecules, large molecules, peptides, oligonucleotides, and biomarkers. The company recently moved to a state-of-the-art GLP/GCP-accredited laboratory near Manchester, UK.

“Welcoming Alderley Analytical to our group is a pivotal step in Synexa’s growth strategy, enhancing our capabilities in bioanalytical services and broadening our geographic reach as a leading European specialist biomarker and bioanalysis services company. By combining two very complementary companies, the group can now offer an even more comprehensive range of services to an enlarged customer base, both in large and small molecule drug development and ranging from pre-clinical work to phase III clinical studies. We are delighted to welcome the Alderley team to Synexa and look forward to combining our strengths.”– commented the CEO of Synexa Life Sciences, Emile Lens.

Paul Holme, CEO and Co-Founder of Alderley Analytical, commented: “We are thrilled to join forces with Synexa Life Sciences. This step represents a significant opportunity to enhance our teams’ bioanalytical services and broaden our impact on drug development. We are excited by the new possibilities of providing greater value to our customers and supporting the further advancement of innovative therapies.”

About Synexa Life Sciences

Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays. Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis. We partner with our customers to contribute to the furtherment of scientific development and, ultimately, better management and treatment of human health.

Synexa Life Sciences is backed by Gilde Healthcare, a leading European healthcare investment firm.

About Alderley Analytical

Alderley Analytical is an independent Contract Research Organisation (CRO) specialising in bioanalytical services to support drug development through discovery, pre-clinical safety testing, and clinical development. As a GLP and GCP-accredited laboratory, Alderley Analytical offers regulatory compliance and method validation according to current guidelines, providing reliable and accurate bioanalytical results. Their commitment to excellent communication ensures that clients are well-supported and informed throughout the process.

For further information, please contact:

Emile Lens
Chief Executive Officer
Synexa Life Sciences
contactus@synexagroup.com

www.synexagroup.com

Record changed: 2025-09-25